EP Patent

EP3987027A1 — Endonuclease-resistant messenger rna and uses thereof

Assigned to ModernaTx Inc · Expires 2022-04-27 · 4y expired

What this patent protects

The present disclosure provides messenger RNAs (mRNAs) with alterations which provide increased endonuclease resistance to the mRNA and methods and uses thereof.

USPTO Abstract

The present disclosure provides messenger RNAs (mRNAs) with alterations which provide increased endonuclease resistance to the mRNA and methods and uses thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP3987027A1
Jurisdiction
EP
Classification
—
Expires
2022-04-27
Drug substance claim
No
Drug product claim
No
Assignee
ModernaTx Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.